In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval

Executive Summary

Genentech has been clear that it intends to appeal FDA's determination that the breast cancer indication for Avastin should be revoked, but the agency may not let the appeal go forward.
Advertisement

Related Content

FDA “Regulatory Flexibility” On Accelerated Approval Must Result In Some Withdrawals
Roche Looks Ahead To 2011, But Avastin Woes And Other Concerns Could Pose Challenges
Avastin Data, Policy Implications Warrant Hearing On Breast Cancer Use, Genentech Tells FDA
FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints
How The Avastin Appeal Will Proceed
How The Avastin Appeal Will Proceed
Avastin's Next Stop May Be Hearing As FDA Starts Withdrawal Process For Breast Cancer Claim
Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics
With Avastin Approval For Breast Cancer, Will More Patients Hit Price Cap?
Progression-Free Survival Represents Clinical Benefit, But How Much? – ODAC

Topics

Advertisement
UsernamePublicRestriction

Register

PS052960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel